



Description of Participants Enrolled in the RCT of Psilocybin-Assisted Psychotherapy to Address Distress in Advanced Cancer

Catherine Pappano, Katarina Rees, Caroline Harrison, MPH, Stacy Fischer, MD, Kristin Kilbourn, PhD, MPH
Department of Psychology | University of Colorado Denver/Anschutz Medical Campus




Background and Purpose

- Living with advanced cancer is associated with elevated levels of anxiety, depression, and existential distress.^{1,2}
- Few evidence-based interventions exist to address these unique challenges.
- This NIH-funded, multi-site, randomized-controlled trial will examine the effects of psilocybin-assisted psychotherapy (PAP) on psychiatric and existential distress in people with advanced cancer.
- This poster summarizes key demographics of participants enrolled at the University of Colorado site.

Methods

- Data was collected through screening and baseline surveys

Results



Conclusions

- Enrolled participants are primarily white and well-educated with middle/upper socioeconomic status.
- Most participants report moderate levels of distress at pre-screening and prior experience using psychedelics.
- Further research efforts are required to:
 - Elucidate participant characteristics that predict interest in PAP.
 - Engage and recruit a more diverse and representative population in psychedelic studies.

References

- Teunissen, S. C., Wesker, W., Kruitwagen, C., de Haes, H. C., Voest, E. E., & de Graeff, A. (2007). Symptom prevalence in patients with incurable cancer: a systematic review. *J Pain Symptom Manage*, 34(1), 94-104. <https://doi.org/10.1016/j.jpainsymman.2006.10.015>
- Vehling, S., & Mehnert, A. (2014). Symptom burden, loss of dignity, and demoralization in patients with cancer: a mediation model. *Psychooncology*, 23(3), 283-290. <https://doi.org/10.1002/pon.3417>

